- Patients treated with OTEZLA 30 mg BID achieved significantly greater improvement vs placebo in dactylitis count (mean change of -1.8 vs -1.3, P = 0.0097) and MASES (enthesitis) score (mean change of -1.3 vs -0.9, P = 0.0194) at week 241†
This site is intended for healthcare professionals outside the U.S.
PALACE 1-3 pooled analysis. Data as observed; includes all patients who received OTEZLA 30 mg BID, regardless of whether they were initially randomized to OTEZLA 30 mg BID or placebo patients who were re-randomized to OTEZLA at week 16 or week 24.
Pooled patient data from PALACE 1-3; includes all randomized patients with preexisting enthesopathy (baseline MASES score >0; n = 945) and/or dactylitis (baseline dactylitis count >0; n = 633).
LOCF; for patients who qualified for early escape at week 16, the week 16 value was carried forward.
LOCF, last observation carried forward; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy.
Reference: 1. Gladman DD, Kavanaugh A, Adebajo AO, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (104-week) improvements in enthesitis and dactylitis in patients with psoriatic arthritis: pooled results from three phase III, randomized, controlled trials. Presented at: the 2015 ACR/ARHP Annual Meeting; November 7–11, 2015; San Francisco, CA. Abstract 2888.
Please choose a country